HCA Healthcare rises 2.4% as healthcare stocks rally amid investigator notice

What happened

HCA Healthcare (HCA) rose 2.4% on October 20, 2026, as the healthcare sector rallied and a law firm announced an investor investigation into the company. The stock opened 0.7% above the previous close and closed at $465.75, with trading volume 1.2 times its 20-day average. The move broadly tracked peers: the Healthcare sector median on the day rose 3.0% while the S&P 500 rose 0.3%.

How big was the move

The stock rose 2.4%, a move equal to 1.3 times a typical daily move for this stock. Over the last five sessions the stock rose 1.1% while the S&P 500 over five sessions fell 1.2%. Compared with its sector the stock was 0.6 percentage points worse than the sector median. Market sensitivity is low, with a beta of 0.25, indicating the stock tends to move less than the market.

This session’s gain was therefore best read as largely sector-driven rather than company-specific. The Pomerantz LLP announcement on October 20, 2026, that it is investigating potential claims on behalf of investors in HCA Healthcare, Inc. was reported by GlobeNewsWire and provided a company-specific backdrop, but the sector-wide advance suggests the stock moved with broader healthcare momentum.

The technical picture

The stock traded 4.9% above its 20-day moving average, 8.7% above its 50-day moving average and 4.7% above its 200-day moving average. The 50-day average is below the 200-day average, a sign of a weak longer-term trend, though the stock has spent eight consecutive trading days above the 200-day average. The Relative Strength Index (14 days) stood at 65, inside a neutral range between 30 and 70.

Momentum measures showed a one-month change of rose 9.3% and a three-month change of rose 25.2%, while one year the stock rose 9.3% and was 6.4 percentage points behind the S&P 500. The stock was 16.3% below its 52-week high. Volatility was 30% annualized over 60 days, higher than 70% of its own readings over five years, indicating price swings have increased recently relative to the stock’s historical range.

Fundamentals and valuation

For the four quarters through June 30, 2026, revenue was $78.01 billion, which grew 7.3% from a year earlier; revenue growth one quarter earlier showed growth of 6.7%. Diluted earnings per share were $29.87, and earnings per share growth from a year earlier rose 25.5%. Gross margin was 28.4%, down from 40.9% a year earlier, while operating margin was 15.5% compared with 15.2% a year earlier. Free-cash-flow margin was 7.7% and return on invested capital was 19.4%.

The balance sheet showed net debt of 3.0 times EBITDA, and share count over one year decreased by 7.9%, a sign of significant buybacks. Valuation metrics show the stock at 15.6 times trailing earnings and 15.8 times expected earnings, with a free-cash-flow yield of 6.0%. The price to trailing earnings is higher than 71% of its own readings over the past five years, where the five-year median was 14.4 times earnings. PromtFinance scores rank Value 85 (Strong), Quality 75 (Positive) and Stability 89 (Strong), while Growth is 43 (Weak) and Revisions 45 (Neutral).

Taken together, the company shows solid cash generation and returns on capital but faces a compressed gross margin year over year and relatively modest growth scores. The current valuation sits above much of its recent history, reflecting a premium for the stock’s cash flow and quality metrics despite slower growth readings.

Earnings and analyst expectations

HCA last reported on July 24, 2026, with earnings per share of $7.59 against $7.56 expected, 0.4% above estimates. The company has recorded 11 consecutive quarters beating estimates, and the average surprise over the last four reports was 7.1% above estimates. Typical two-day reaction after recent reports was fell 2.2%.

The next report is scheduled for October 27, 2026. Analysts with ratings number 46 and the consensus rating is Buy, with 63% of those ratings classifying the stock as Buy or Strong Buy. The consensus price target is $461.12, which is 1.0% below the closing price.

What to watch

• October 27, 2026: next earnings report.
• The Pomerantz LLP announcement on Oct. 20, 2026, that it is investigating potential claims on behalf of investors in HCA Healthcare, Inc., reported by GlobeNewsWire.
• Trading volume relative to its 20-day average and sector momentum if the Healthcare sector continues to move in coming sessions.
• Changes to net debt of 3.0 times EBITDA or share count after any capital actions.
• Any analyst revisions ahead of the October 27, 2026, report.